American Society of Hematology

Figure 3.

$Figure 3. Protein array screening of cytokine release in BALF 16 hours after endobronchial administration of LPS or normal saline (NS) in volunteers receiving rhAPC, compared with untreated volunteers. Representative arrays from BALF of volunteers receiving rhAPC or placebo. ENA indicates epithelial neutrophil-activating peptide; GRO, growth regulated gene; MCP, monocyte chemoattractant protein; MDC, monocyte-derived DC; MIG, monokine induced by IFNγ; MIP, macrophage inflammatory protein; SCF, stem cell factor; SDF, stromal cell-derived factor; TARC, thymus and activation-regulated chemokine; EGF, epidermal growth factor; IGF, insulin-like growth factor. An additional 41 cytokines, chemokines, and growth factors were screened, without evidence of modification by rhAPC administration (data not shown). These peptides include oncostatin M (OSM); thrombopoietin (TPO); vascular endothelial growth factor (VEGF); platelet-derived growth factor (PDGF); leptin, brain-derived neurotrophic factor (BDNF); B-lymphocyte chemoattractant (BLC); CKβ8-1; eotaxin-1, -2, and -3; fibroblast growth factor 4 (FGF-4), -6, -7, and -9; Fit-3 ligand; fractalkine; granulocyte chemotactic protein 2 (GCP-2); glial cell line-derived neurotrophic factor (GDNF); hepatocyte growth factor (HGF); insulin-like growth factor binding proteins (IGFBP)-1, -2, -3, and -4; IL-16; IFNγ-inducible protein 10 (IP-10); leukemia inhibitory factor (LIF); LIGHT; MCP-4; macrophage migration inhibitory factor (MIF); MIP-3α; neutrophil-activating protein 2 (NAP-2); neurotrophin (NT)-3 and -4; osteopontin (OPN); pulmonary and activation-regulated chemokine (PARC); placental growth factor (PIGF); TGF-β2 and -β3; and tissue inhibitor of metalloproteinase (TIMP)-1 and -2.$

Protein array screening of cytokine release in BALF 16 hours after endobronchial administration of LPS or normal saline (NS) in volunteers receiving rhAPC, compared with untreated volunteers. Representative arrays from BALF of volunteers receiving rhAPC or placebo. ENA indicates epithelial neutrophil-activating peptide; GRO, growth regulated gene; MCP, monocyte chemoattractant protein; MDC, monocyte-derived DC; MIG, monokine induced by IFNγ; MIP, macrophage inflammatory protein; SCF, stem cell factor; SDF, stromal cell-derived factor; TARC, thymus and activation-regulated chemokine; EGF, epidermal growth factor; IGF, insulin-like growth factor. An additional 41 cytokines, chemokines, and growth factors were screened, without evidence of modification by rhAPC administration (data not shown). These peptides include oncostatin M (OSM); thrombopoietin (TPO); vascular endothelial growth factor (VEGF); platelet-derived growth factor (PDGF); leptin, brain-derived neurotrophic factor (BDNF); B-lymphocyte chemoattractant (BLC); CKβ8-1; eotaxin-1, -2, and -3; fibroblast growth factor 4 (FGF-4), -6, -7, and -9; Fit-3 ligand; fractalkine; granulocyte chemotactic protein 2 (GCP-2); glial cell line-derived neurotrophic factor (GDNF); hepatocyte growth factor (HGF); insulin-like growth factor binding proteins (IGFBP)-1, -2, -3, and -4; IL-16; IFNγ-inducible protein 10 (IP-10); leukemia inhibitory factor (LIF); LIGHT; MCP-4; macrophage migration inhibitory factor (MIF); MIP-3α; neutrophil-activating protein 2 (NAP-2); neurotrophin (NT)-3 and -4; osteopontin (OPN); pulmonary and activation-regulated chemokine (PARC); placental growth factor (PIGF); TGF-β2 and -β3; and tissue inhibitor of metalloproteinase (TIMP)-1 and -2.

This Feature Is Available To Subscribers Only